Session » Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster II

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1400

Beneficial Effect of Anti-IL-6 Blockade on Insulin Resistance and Insulin Sensitivity in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1413

Cytokine-Induced Aire Activity in Rheumatoid Arthritis Fibroblast-like Synoviocytes Regulates Expression of Interferon-γ Response Genes

9:00AM-11:00AM: Abstract Number: 1416

Higher Expression of Type 1 Interferon in Synovitis of Patient with Undifferentiated Arthritis before They Met Rheumatoid Arthritis Criteria Compared to Established Rheumatoid Arthritis. a Retrospective Study with 14 Years of Follow-up

9:00AM-11:00AM: Abstract Number: 1407

Huntingtin Interactin Protein 1 (HIP1) Regulates Invasiveness, Actin Filament and Lamellipodia Formation in Rheumatoid Arthritis Fibroblast-like Synoviocytes (FLS)

9:00AM-11:00AM: Abstract Number: 1404

Hydrogen Sulfide Metabolism and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1402

In RA, Becoming Seronegative over the 1st Year of DMARD Treatment Does Not Improve Chances of Drug-Free Remission in the Long-Term

9:00AM-11:00AM: Abstract Number: 1403

Mediterranean Diet Is Inversely Associated with Risk of Rheumatoid Arthritis: A Swedish Population Based Case-Control Study

9:00AM-11:00AM: Abstract Number: 1406

Methods for Generating Multiple High-Dimensional Analyses of Cryopreserved Synovial Tissue Developed By the Accelerating Medicines Partnership RA/SLE Network

9:00AM-11:00AM: Abstract Number: 1417

Mitophagy Defect in Fibroblast-like Synoviocytes of Rheumatoid Arthritis Is Improved By Pyruvate Treatment

9:00AM-11:00AM: Abstract Number: 1401

Persistence of Mast Cell-Rich Synovitis Is Associated with Lack of Response to Synthetic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1411

Protein Tyrosine Phosphatase Non-Receptor 22 / C-Src Tyrosine Kinase Complex Down-Regulated in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1414

Stimulation with Resistin Upregulates Chemokine Production By Fibroblast-like Synoviocytes from Patients with Rheumtoid Arthritis

9:00AM-11:00AM: Abstract Number: 1408

The Cation Channel TRPV2 Decreases Rheumatoid Arthritis Fibroblast-like Synoviocyte Invasiveness By Inhibiting RhoA Activation, Cell Adhesion and Actin Cytoskeleton Changes

9:00AM-11:00AM: Abstract Number: 1399

Tissues Are Differently Modulated By Tocilizumab and Methotrexate; Assessment of Connective Tissue Metabolites in the Ambition Study

9:00AM-11:00AM: Abstract Number: 1415

TNF-Induced IRF1 Is Critical for the Inflammatory Gene Expression in Fibroblast-like Synoviocytes

9:00AM-11:00AM: Abstract Number: 1410

Tyrosine Kinase Receptor Axl Is Down Regulated in Highly Inflamed Rheumatoid Synovium and Negatively Correlates with Markers of Disease Activity

9:00AM-11:00AM: Abstract Number: 1409

Ursolic Acid Promotes Apoptosis of Rheumatoid Athritis Synovial Fibroblasts By Upregulating Noxa Expression and Recruiting E3 Ligase Mule to Degrade Mcl-1

9:00AM-11:00AM: Abstract Number: 1405

Using Flow and Mass Cytometry to Demonstrate Robust Tissue Processing to Query Molecular Heterogeneity in Phase 1 of the Accelerating Medicines Partnership (AMP) – RA Network

9:00AM-11:00AM: Abstract Number: 1412

Yra-1909 suppresses Production of Pro-Inflammatory Mediators and MMPs through Downregulating Akt, p38, JNK and NF-κb Activation in Rheumatoid Arthritis Fibroblast-like Synoviocytes

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].